Bradley J Carver

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Molecular Docking

Papillary Thyroid

Small Cell Lung Cancer

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Peter Cornelius, Benjamin A Mayes, John S Petersen, David J Turnquist, Pierre J Dufour, Andrew J Dannenberg, James M Shanahan, Bradley J Carver
Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity. Molecular cancer therapeutics 23 (5) (2024)
Peter Cornelius, Benjamin A Mayes, John S Petersen, David J Turnquist, Pierre J Dufour, Andrew J Dannenberg, James M Shanahan, Bradley J Carver
Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity. Molecular cancer therapeutics 23 (5) (2024)
Peter Cornelius, Benjamin A Mayes, John S Petersen, David J Turnquist, Pierre J Dufour, Andrew J Dannenberg, James M Shanahan, Bradley J Carver
Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity. Molecular cancer therapeutics 23 (5) (2024)
Peter Cornelius, Benjamin A Mayes, John S Petersen, David J Turnquist, Pierre J Dufour, Andrew J Dannenberg, James M Shanahan, Bradley J Carver
Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity. Molecular cancer therapeutics 23 (5) (2024)
Peter Cornelius, Benjamin A Mayes, John S Petersen, David J Turnquist, Pierre J Dufour, Andrew J Dannenberg, James M Shanahan, Bradley J Carver
Pharmacological Characterization of SDX-7320/Evexomostat: a Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-Tumor and Anti-Metastatic Activity. Molecular cancer therapeutics (2024)